MacroGenics, Inc.

NASDAQ:MGNX

Biotechnology

Healthcare
$2.05 +2.02%

+$0.08 today

Market cap
$131.01M
Beta
1.20
P/E (TTM)
-3.6
EPS (TTM)
-$1.11
52W Low $1.19High $4.64

Volume 0.57M

Average 0.98M

MGNX Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

MacroGenics, Inc.NASDAQ: MGNX

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses declines year over year

Q1 FY2026 operating expenses of $43M fell 11.6% year over year, behind the -10.6% change in trailing-twelve-month operating expenses. Sequentially, it rose 3.6% from the prior quarter. Over 3 fiscal years it compounded at -12.1% a year.

Context

  • Operating expenses amounted to 119.8% of revenue in FY2025, down 46.4 pp from a year earlier.
  • Operating expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -11.6% toward the trailing-twelve-month pace of -10.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$43M+3.6% QoQ
Last fiscal yearDec 2025
$179.16M-27.4% YoY
LTMMar 2026
$173.51M-10.6% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.6%——
1 year-27.4%——
3-year CAGR-12.1%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
179.16M USD
Year-over-year change
-27.4%
4-year CAGR
-10.2%

Operating Expenses vs competitors

How MGNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.6% is the 7th highest of 11, against a peer median of -2.8%.
  • Operating expenses amounts to 110.5% of revenue for MGNX, versus a peer median of 10268.7%.
MGNX Competitors
Operating Expenses for MGNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$173.51M USD-10.6%-12.1%110.5%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$144.89M USD-39.4%-12.4%—
WHWKWhitehawk Therapeutics IncLTM Mar 2026$122.7M USD+143.6%+40.1%—
CNTBConnect Biopharma Holdings LimitedFY2025$58.14M USD+19.9%-21.3%90840.6%
OVIDOvid Therapeutics Inc.LTM Mar 2026$54.82M USD-4.8%-4.7%769.8%
STTKShattuck Labs, Inc.LTM Mar 2026$51.84M USD-32.4%+34.1%5184.4%
CNTXContext Therapeutics Inc.LTM Mar 2026$43.51M USD+37.6%+37.2%—
IFRXInflaRx N.V.LTM Mar 2026€35.14M EUR-30.5%+8.4%119798.7%
COYACoya Therapeutics, Inc.LTM Mar 2026$29.92M USD+225.6%+73.5%376.8%
CLNNClene Inc.LTM Mar 2026$20.57M USD-27.1%-21.9%15353.0%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$14.22M USD-0.8%-29.6%—
Peer median (excluding MGNX) —-2.8%+1.8%10268.7%

Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75.64M150.02M57.19M148.34M149.5M
Cost of Revenue2.65M7.38M8.22M12.3M43.18M
Gross Profit72.99M142.63M48.97M136.04M106.32M
Gross Margin96.5%95.1%85.6%91.7%71.1%
Research & Development214.58M207.03M166.58M177.19M140M
Selling, General & Admin63.01M58.95M52.19M71.05M39.16M
Operating Expenses275.79M264.05M217.22M246.62M179.16M
Depreciation & Amortization11.26M11.87M9.65M7.54M7.17M
EBITDA(190.86M)(107.89M)2.02M(57.37M)(59.61M)
EBITDA Margin-252.3%-71.9%3.5%-38.7%-39.9%
Operating Income(202.8M)(121.42M)(168.24M)(110.58M)(72.84M)
Operating Margin-268.1%-80.9%-294.2%-74.5%-48.7%
Interest Income680K1.7M9.69M9.42M3.4M
Interest Expense001.43M1.12M8.51M
Other Income / Expenses680K1.66M159.19M44.56M(2.45M)
Income Before Tax(202.12M)(119.76M)(9.06M)(66.02M)(75.29M)
Pre-Tax Margin-267.2%-79.8%-15.8%-44.5%-50.4%
Income Tax Expense000944K(672K)
Net Income(202.12M)(119.76M)(9.06M)(66.97M)(74.62M)
Net Margin-267.2%-79.8%-15.8%-45.1%-49.9%
EPS (Basic)(3.18)(1.95)(0.15)(1.07)(1.18)
EPS (Diluted)(3.18)(1.95)(0.15)(1.07)(1.18)
Weighted Avg Shares59.94M61.41M61.93M62.62M63.16M
Weighted Avg Shares (Diluted)59.94M61.43M61.93M62.62M63.16M

MacroGenics, Inc.

NASDAQ:MGNX

Intrinsic Alpha fair value

Locked

Current Price

$2.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.